NBY: AI 评分 45/100 — AI 分析 (4月 2026)

NovaBay Pharmaceuticals, Inc. focuses on developing and commercializing innovative anti-infective products for the eyecare and skincare markets. Their key product, Avenova, addresses hygiene and anti-infective needs, while the DERMAdoctor brand offers a range of dermatological solutions.

Key Facts: Price: $1.45 AI Score: 45/100 Sector: Healthcare

公司概况

概要：

NovaBay Pharmaceuticals, Inc. (NBY) is a revenue-generating biotech firm specializing in the eyecare and skincare markets with its flagship Avenova solution and DERMAdoctor brand, boasting a high profit margin and significant dividend yield, positioning it for growth in targeted therapeutic areas.

NBY是做什么的？

NovaBay Pharmaceuticals, Inc., founded in 2000 and headquartered in Emeryville, California, is a pharmaceutical company dedicated to developing and commercializing innovative anti-infective products. Originally named NovaCal Pharmaceuticals, the company rebranded to NovaBay Pharmaceuticals in 2007, marking a strategic shift towards its current focus. The company's primary product is Avenova, a proprietary solution designed for removing foreign materials, including microorganisms and debris, from the skin around the eye, particularly the eyelid. Avenova is available through various channels, including retailers, digital beauty platforms, and online sales. In addition to Avenova, NovaBay offers wound care products under the NeutroPhase and PhaseOne brands. These products are designed to aid in wound healing and infection control. Furthermore, NovaBay has expanded its portfolio to include dermatological solutions through the DERMAdoctor brand. This line addresses a wide range of skincare concerns, such as keratosis pilaris, rosacea, eczema, anti-aging, SPF protection, hyperhidrosis, excessive hair, and acne. DERMAdoctor products are sold through retailers, digital channels, and distributors. NovaBay's diversified product offerings and multi-channel distribution strategy reflect its commitment to serving the eyecare, skincare, and wound care markets. The company continues to innovate and expand its product lines to meet the evolving needs of its customers.

NBY的投资论点是什么？

NovaBay Pharmaceuticals presents a notable market position due to its established presence in the eyecare and skincare markets, driven by its key product Avenova and the DERMAdoctor brand. The company's high profit margin of 114.6% and gross margin of 54.6% indicate strong profitability and efficient operations. With a dividend yield of 55.94%, NBY offers a substantial return to investors. Growth catalysts include expanding the market reach of Avenova through strategic partnerships and increasing sales of DERMAdoctor products through digital channels. The company's focus on niche markets within the broader skincare and eyecare sectors allows for targeted growth strategies. The current market capitalization of $0.04 billion suggests significant upside potential if the company can execute its growth plans effectively and maintain its profitability.

NBY在哪个行业运营？

NovaBay Pharmaceuticals operates in the biotechnology sector, focusing on the eyecare and skincare markets. The global skincare market is projected to reach billions of dollars in the coming years, driven by increasing consumer awareness and demand for advanced skincare solutions. The competitive landscape includes companies like ADXN, IBO, KTTA, MTNB, and PMCB, which also offer various skincare and healthcare products. NovaBay differentiates itself through its Avenova solution and the DERMAdoctor brand, targeting specific skincare concerns and leveraging multiple distribution channels to reach a broad customer base. The company's focus on innovation and niche markets positions it for continued growth within the competitive biotechnology industry.

Biotechnology

Healthcare

NBY有哪些增长机遇？

Expansion of Avenova Market Reach: Avenova, NovaBay's flagship product for eyelid hygiene, has significant growth potential through increased market penetration and strategic partnerships. The market for eyelid hygiene products is expanding, driven by growing awareness of conditions like blepharitis and dry eye. By partnering with eyecare professionals and expanding distribution channels, NovaBay can capture a larger share of this market. The timeline for this growth opportunity is immediate and ongoing, with continuous efforts to enhance market reach and brand awareness.
Increased Sales of DERMAdoctor Products: The DERMAdoctor brand offers a diverse range of dermatological solutions targeting various skincare concerns. By focusing on digital marketing and expanding online sales channels, NovaBay can drive increased sales of DERMAdoctor products. The global market for dermatological products is substantial, with increasing demand for specialized skincare solutions. The timeline for this growth opportunity is ongoing, with continuous product innovation and marketing efforts to attract new customers and retain existing ones.
Strategic Partnerships and Acquisitions: NovaBay can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other companies in the healthcare and skincare sectors can provide access to new technologies, distribution networks, and customer segments. The timeline for this growth opportunity is medium-term, as it requires careful evaluation of potential partners and acquisition targets. Successful partnerships and acquisitions can significantly enhance NovaBay's competitive position and growth prospects.
New Product Development and Innovation: Investing in research and development to create new and innovative products is crucial for long-term growth. NovaBay can focus on developing novel formulations and delivery systems for its eyecare and skincare products. The market for innovative healthcare solutions is constantly evolving, with consumers seeking advanced and effective treatments. The timeline for this growth opportunity is long-term, as it requires sustained investment in R&D and clinical trials. Successful product development can lead to significant revenue growth and market share gains.
International Expansion: Expanding into international markets represents a significant growth opportunity for NovaBay. By targeting specific regions with high demand for its products, NovaBay can diversify its revenue streams and reduce its reliance on the US market. The global market for eyecare and skincare products is vast, with significant growth potential in emerging economies. The timeline for this growth opportunity is medium to long-term, as it requires careful market research, regulatory approvals, and establishment of distribution networks. Successful international expansion can significantly enhance NovaBay's long-term growth prospects.

Market Cap of $0.04B indicates micro-cap status with potential for high growth.
P/E ratio of 12.96 suggests the company is potentially undervalued compared to its earnings.
Profit Margin of 114.6% demonstrates strong profitability and efficient cost management.
Gross Margin of 54.6% highlights the company's ability to maintain healthy profit margins on its products.
Dividend Yield of 55.94% provides a substantial return to investors, making it attractive for income-seeking portfolios.

NBY提供哪些产品和服务？

Develops and sells Avenova, a solution for removing foreign materials from the skin around the eye.
Offers wound care products under the NeutroPhase and PhaseOne brands.
Provides dermatological solutions under the DERMAdoctor brand.
Addresses skincare concerns such as keratosis pilaris, rosacea, and eczema.
Offers anti-aging and SPF products.
Provides solutions for hyperhidrosis, excessive hair, and acne.
Sells products through retailers, digital beauty channels, and distributors.
Markets and sells products online.

NBY如何赚钱？

Develops and manufactures eyecare, skincare, and wound care products.
Sells products directly to consumers through online channels.
Distributes products through retailers and digital beauty channels.
Partners with distributors to reach a wider customer base.

Individuals seeking solutions for eyelid hygiene.
Patients requiring wound care products.
Consumers looking for dermatological solutions for various skin conditions.
Retailers and distributors selling eyecare and skincare products.

Proprietary formulations for Avenova and other products.
Established brand recognition in the eyecare and skincare markets.
Multi-channel distribution strategy including online, retail, and distribution partners.
Focus on specific skincare concerns and niche markets.

什么因素可能推动NBY股价上涨？

Upcoming: Potential FDA approvals for new product formulations.
Ongoing: Expansion of distribution partnerships for Avenova.
Ongoing: Increased marketing efforts to drive sales of DERMAdoctor products.
Upcoming: Release of quarterly earnings reports demonstrating revenue growth.
Ongoing: Development and launch of new dermatological solutions.

NBY的主要风险是什么？

Potential: Dilution risk due to the need for additional capital.
Potential: Competition from larger pharmaceutical and skincare companies.
Potential: Regulatory hurdles and compliance costs.
Ongoing: Dependence on key products for revenue generation.
Potential: Economic downturn affecting consumer spending on skincare products.

NBY的核心优势是什么？

Proprietary Avenova solution for eyelid hygiene.
Established DERMAdoctor brand with diverse skincare offerings.
High profit margin of 114.6%.
Multi-channel distribution strategy.

NBY的劣势是什么？

Small market capitalization of $0.04B.
Limited number of employees (13).
Reliance on key products for revenue generation.
Potential competition from larger pharmaceutical companies.

NBY有哪些机遇？

Expansion of Avenova market reach through strategic partnerships.
Increased sales of DERMAdoctor products through digital channels.
Strategic acquisitions to expand product portfolio.
International expansion into new markets.

NBY面临哪些威胁？

Competition from established players in the eyecare and skincare markets.
Regulatory challenges and compliance requirements.
Potential product liability claims.
Economic downturn affecting consumer spending on skincare products.

NBY的竞争对手是谁？

Addex Therapeutics Ltd — Focuses on pharmaceutical products. — (ADXN)
IBO Technology Company Limited — Engaged in technology solutions. — (IBO)
Pasithea Therapeutics Corp. — Focuses on mental health therapeutics. — (KTTA)
Matinas BioPharma Holdings, Inc. — Develops lipid nanocrystal products. — (MTNB)
PharmaCyte Biotech, Inc. — Focuses on cancer therapies. — (PMCB)

Key Metrics

Price: $1.45 (+19.83%)
Market Cap: $38.0M
P/E Ratio: 13.14
MoonshotScore: 45/100

常见问题

What does NovaBay Pharmaceuticals, Inc. (NBY) do?

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that develops and sells eyecare and skincare products, both domestically and internationally. Their primary product, Avenova, is a solution used for removing foreign materials and microorganisms from the skin around the eyes. Additionally, they offer wound care products under the NeutroPhase and PhaseOne brands, and a variety of dermatological solutions through their DERMAdoctor brand, addressing conditions like acne, eczema, and aging. NovaBay distributes its products through retailers, digital beauty channels, and online platforms.

Is NBY stock a good buy?

NBY stock presents a mixed picture for potential investors as of March 3, 2026. On one hand, the company boasts a high profit margin of 114.6% and a substantial dividend yield of 55.94%, suggesting strong profitability and return potential. However, its micro-cap status with a market capitalization of $0.04 billion and a beta of 0.01 indicate higher risk and volatility. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in NBY, weighing the potential for high returns against the inherent risks of a small-cap biotech company.

What are the risks of investing in NBY?

Investing in NovaBay Pharmaceuticals (NBY) carries several risks. As a micro-cap company, NBY faces potential dilution risk if it needs to raise additional capital through stock offerings. Competition from larger, more established pharmaceutical and skincare companies poses a threat to market share. Regulatory hurdles and compliance costs can also impact profitability. Additionally, the company's reliance on key products for revenue generation makes it vulnerable to market shifts and product-specific challenges. Economic downturns could reduce consumer spending on skincare products, affecting sales.

What catalysts could move NBY stock?

Several catalysts could potentially move NBY stock. Upcoming FDA approvals for new product formulations could boost investor confidence and drive stock appreciation. Expansion of distribution partnerships for Avenova would increase market reach and sales. Increased marketing efforts to promote DERMAdoctor products could also lead to revenue growth. Positive quarterly earnings reports demonstrating revenue growth and profitability would likely have a positive impact. Finally, the successful development and launch of new dermatological solutions could attract new customers and drive stock value.

What is NBY stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for NBY stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed financial analysis, considering factors such as revenue growth, profitability, and industry trends. Investors should conduct their own due diligence and consider various valuation methods to determine a reasonable price target for NBY stock, taking into account the inherent risks and uncertainties associated with investing in a small-cap biotech company.